High-dose naltrexone therapy for cocaine-alcohol dependence

American Journal on Addictions

Volumn 18, Issue 5, 2009, Pages 356-362

  Schmitz, Joy M ^a   Lindsay, Jan A ^a   Green, Charles E ^b   Herin, David V ^c   Stotts, Angela L ^b   Gerard Moeller, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COCAINE; NALTREXONE; PLACEBO; RIBOFLAVIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTINGENCY MANAGEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; TREATMENT OUTCOME; URINALYSIS;

ADULT; ALCOHOLISM; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE;

EID: 71049118584     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490903077929     Document Type: Article

References (36)

1. Heil SH, Badger GJ, Higgins ST. Alcohol dependence among cocainedependent outpatients: demographics, drug use, treatment outcome and other characteristics. J Stud Alcohol. 2001;62:14-22.
2. Carroll KM, Rounsaville BJ, Gordon LT, et al. Alcoholism in treatmentseeking cocaine abusers: clinical and prognostic significance. J Stud Alcohol. 1993;54:199-208.
3. Weiss RD, Mirin SM, Griffin ML, Michael JL. Psychopathology in cocaine abusers. Changing trends. J Nerv Ment Dis. 1988;176:719-725.
4. Schmitz JM, Bordnick PS, Kearney ML, Fuller SM, Breckenridge JK. Treatment outcome of cocaine-alcohol dependent patients. Drug Alcohol Depend. 1997;47:55-61.
5. Brady KT, Sonne S, Randall CL, Adinoff B, Malcolm R. Features of cocaine dependence with concurrent alcohol abuse. Drug Alcohol Depend. 1995;39:69-71.
6. Brower KJ, Blow FC, Hill EM, Mudd SA. Treatment outcome of alcoholics with and without cocaine disorders. Alcohol Clin Exp Res. 1994;18:734-739.
7. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl). 1998;139:44-52.
8. Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict. 2004;13:333-341.
9. McCaul ME. Efficacy of natrexone for alcoholics with and without comorbid opiate or cocaine dependence. Alcoholism: Clinical and experimental research. 1996;20:216A-218A.
10. Oslin DW, Pettinati HM, Volpicelli JR,Wolf AL, Kampman KM, O'Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat. 1999;16:163-167.
11. Pettinati HM, Kampman KM, Lynch KG, et al. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008;34:378-390.
12. Kosten TR, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70:315-325.
13. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63:219-228.
14. Schmitz JM, Rhoades HM, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol. 1998;6:162-168.
15. Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008;94:142-150.
16. Sayre SL, EvansM, Hokanson PS, et al. "Who gets in?" Recruitment and screening processes of outpatient substance abuse trials. Addict Behav. 2004;29:389-398.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
18. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders-patient edition (SCID -I / P, Version 2.0). 1995: Biometric Research Department, NY.
19. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl. 1994;12:70-75.
20. Marlatt GA. Relapse prevention: theoretical rationale and overview of the model.In: Marlatt GA, Gordon JR, eds. Relapse prevention. New York, NY: Guilford Press; 1985:3-70.
21. Schmitz JM, Oswald LM, Jacks SD, Rustin T, Rhoades HM, Grabowski J. Relapse prevention treatment for cocaine dependence: group vs. individual format. Addict Behav. 1997;22:405-418.
22. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26:167-180. (Pubitemid 32186424)
23. Budney AJ, Higgins ST. A community reinforcement plus vouchers approach: Treating cocaine addiction. Therapy manuals for drug addiction. 1998, USDHHS NIH.
24. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
25. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20:1412-1417.
26. Mooney ME, Sayre SL, Green C, Rhoades H, Schmitz JM. Comparing measures of medication taking in a pharmacotherapy trial for cocaine dependence. Addictive Disorders & Their Treatment. 2004;3:165-173.
27. Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr. 1997;175:208-220.
28. Sanchez-Craig M, Wilkinson DA, Davila R. Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers. Am J Public Health. 1995;85:823-828.
29. SAS, The SAS System for Windows (Version 9.13). 2006, SAS Institute Inc.: Cary, NC.
30. Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebocontrolled trial that combines disulfiram and naltrexone for treating cooccurring cocaine and alcohol dependence. Addict Behav. 2008;33:651-667.
31. Oslin DW, Lynch KG, Pettinati HM, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res. 2008;32:1299-1308.
32. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-1625.
33. Smith JE, Meyers RJ, Miller WR. The community reinforcement approach to the treatment of substance use disorders. Am J Addict. 2001;10 Suppl: p. 51-59.
34. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152:613-615.
35. Grassi MC, Cioce AM, Giudici FD, Antonilli L, Nencini P. Shortterm efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacol Res. 2007;55:117-121.
36. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A metaanalysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101:192-203.